InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,971.20
(
0.55%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
70.92
(
0.30%
)
Bitcoin
91,998.46
(
2.37%
)
Post# of 665198
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

lukin4winners

Send PM Follow Ignore
Followers 795
Posts 118388
Boards Moderated 0
Alias Born 11/20/2004

lukin4winners

Re: None

Tuesday, 09/27/2022 2:00:43 PM

Tuesday, September 27, 2022 2:00:43 PM

Post# of 665198
JSPR .86 positive clinical news : REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data from the company’s investigator-sponsored study of JSP191 as a conditioning agent in the treatment of Fanconi Anemia were presented at the annual conference of the Inborn Errors Working Party (IEWP), a research group of the European Society of Blood and Marrow Transplantation, held on September 23-25, 2022, in Paris, France
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up